Aldeyra Therapeutics (NASDAQ:ALDX) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.
Other equities analysts have also recently issued reports about the stock. Cantor Fitzgerald set a $30.00 price objective on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, January 29th. Citigroup started coverage on shares of Aldeyra Therapeutics in a research note on Tuesday, December 4th. They issued a “buy” rating and a $23.00 price objective for the company. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 12th. Finally, BidaskClub upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, January 10th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Aldeyra Therapeutics has an average rating of “Buy” and an average price target of $30.40.
Shares of NASDAQ:ALDX opened at $7.75 on Tuesday. Aldeyra Therapeutics has a 52 week low of $6.75 and a 52 week high of $16.70. The firm has a market capitalization of $203.66 million, a price-to-earnings ratio of -5.54 and a beta of 0.82. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.82 and a quick ratio of 4.82.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Recommended Story: Bear Market – How and Why They Occur
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.